astrazeneca
hit
drug
failure
shares
angloswedish
drug
closed
uk
trade
failure
iressa
drug
major
clinical
trial
lung
cancer
drug
significantly
prolong
survival
patients
disease
setback
group
follows
rejection
us
october
anticoagulant
pill
exanta
meanwhile
another
major
money
spinners
cholesterol
drug
crestor
facing
mounting
safety
concerns
would
two
three
blockbuster
drugs
meant
power
company
forward
failing
weve
got
risks
crestor
said
nick
turner
analyst
brokers
jefferies
astrazeneca
hoped
pitch
iressa
drug
rival
medicine
tarceva
iressa
proved
better
placebo
extending
lives
trial
involving
patients
tarceva
made
osi
pharmaceuticals
genentech
roche
already
proved
successful
helping
prolong
life
lung
cancer
patients
aztrazeneca
appointed
new
executive
director
board
john
patterson
charge
drug
development
company
said
mr
patterson
would
make
substantial
changes
clinical
organisation
processes
determined
improve
development
regulatory
performance
restore
confidence
company
value
shareholders
said
chief
executive
tom
mckillop
